Sonoma Pharmaceuticals (SNOA) Net Income towards Common Stockholders (2010 - 2026)
Sonoma Pharmaceuticals' (SNOA) quarterly Net Income towards Common Stockholders came in at -$581000.0 in Q1 2026, up 25.13% year-on-year from -$464321.3 in Q1 2025, and up 29.06% quarter-over-quarter from -$819000.0 in Q4 2025.
Sonoma Pharmaceuticals (SNOA) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Sonoma Pharmaceuticals' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$581000.0 for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 25.13% year-over-year to -$581000.0 in Q1 2026; TTM through Mar 2026 was -$3.2 million, a 8.16% increase from a year earlier, with the FY2026 full-year figure at -$3.2 million, up 8.16% from the prior year.
- Net Income towards Common Stockholders improved to -$581000.0 in Q1 2026 per SNOA's latest filing, from -$819000.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$534000.0 in Q3 2025 and bottomed at -$1.9 million in Q4 2022.
- The 5-year median for Net Income towards Common Stockholders is -$972500.0 (2022), against an average of -$1.0 million.
- Across the five-year window, Net Income towards Common Stockholders sank 917.0% in 2022 and soared 58.89% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$1.9 million in 2022, then jumped by 55.34% to -$866000.0 in 2023, then decreased by 7.16% to -$928000.0 in 2024, then increased by 11.75% to -$819000.0 in 2025, then rose by 29.06% to -$581000.0 in 2026.
- Per Business Quant, the three latest SNOA Net Income towards Common Stockholders figures stand at -$581000.0 (Q1 2026), -$819000.0 (Q4 2025), and -$534000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Sonoma Pharmaceuticals | 1.95 Mn | -445,560.06 | 2.18 Mn | -581,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -581,000.00 |
| Dec 31, 2025 | -819,000.00 |
| Sep 30, 2025 | -534,000.00 |
| Jun 30, 2025 | -1.24 Mn |
| Mar 31, 2025 | -776,000.00 |
| Dec 31, 2024 | -928,000.00 |
| Sep 30, 2024 | -610,000.00 |
| Jun 30, 2024 | -1.14 Mn |
| Mar 31, 2024 | -1.07 Mn |
| Dec 31, 2023 | -866,000.00 |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | -1.42 Mn |
| Mar 31, 2023 | -1.31 Mn |
| Dec 31, 2022 | -1.94 Mn |
| Sep 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -887,000.00 |
| Sep 30, 2021 | -100,000.00 |
| Jun 30, 2021 | -1.10 Mn |
| Mar 31, 2021 | -228,000.00 |
| Dec 31, 2020 | -24,000.00 |